Navigation Links
Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing,Promising Antitumor Activity in Multiple Myeloma at ASCO

E-1.

TIME-2 is a Phase 2/3 trial in patients with relapsed-refractory multiple myeloma. The multi-site, open-label trial will be conducted primarily in the US and Europe. TIME-2 will compare three different dose groups of tanespimycin each in combination with bortezomib. Eligible patients must have failed three prior multiple myeloma regimens, including one each of bortezomib and lenalidomide (Revlimid(R)). The primary endpoint is objective response rate.

TIME-1 is a Phase 3 trial in patients with disease relapse following a single prior course of treatment (first-relapse). It is a randomized, open- label, multi-center international trial with a primary endpoint of progression free survival (PFS). The trial will compare two groups: patients treated with bortezomib plus tanespimycin and patients treated with bortezomib alone.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Kosan's proprietary formulation of tanespimycin (KOS-953) is currently in Phase 1 and 2 clinical trials, primarily for multiple myeloma in combination with Velcade(R) (bortezomib) and HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). In addition, intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors.
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
4. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
5. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:8/29/2014)... 29, 2014  United Therapeutics Corporation (NASDAQ: ... for the District of New Jersey ... case against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... ruled that U.S. Patent No. 6,765,117 is both valid ... marketing its generic product until the expiration of that ...
(Date:8/29/2014)... -- According to the new research ... Reagent, Primer, Probe, Custom Oligos), End-User (Research, Pharmaceutical ... NGS, DNA, RNAi) - Global Forecast to 2019" ... is expected to reach $1,712.1 Million by 2019 ... CAGR of 9.8% from 2014 to 2019.. ...
(Date:8/29/2014)... , Aug. 29, 2014  Unilife Corporation ("Unilife" or ... today that it intends to release its financial results ... June 30, 2014 after market trading ends on Tuesday, ... a conference call for 4:30 p.m. U.S. EDT on ... 6:30 a.m. AEST), to review the Company,s financial results, commercial ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that ... Health Care Conference on Wednesday, March 9, 2011 at 11:00 ... Interested parties may access a live webcast of the presentation ... It is recommended that listeners log on 15 ...
... A new ad campaign warns Mississippi legislators that ... prescription drug benefits and undermine the ability of pharmacy ... Mississippi families and businesses, said the Pharmaceutical Care Management ... put the State Board of Pharmacy (instead of the ...
Cached Medicine Technology:Onyx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference 2New Ad Campaign: Secret Provision Raises Taxes on Prescription Drug Benefits, Creates 'Conflict of Interest' 2
(Date:9/2/2014)... Kicking blog MichaelHusted.com is featuring an interview ... role as a kicking coach, his kicking business, and on ... retired NFL kicker Michael Husted author of HustedKicking.com. , "Anthony ... one of the top pro free agent kickers out there,” ... at our 2014 Pro Camp and I was impressed with ...
(Date:9/2/2014)... 2014: The fact that mechanical heart valves increase risks ... from the ROPAC registry presented for the first time ... Professor Jolien W. Roos-Hesselink, co-chair with Professor Roger Hall ... 1.4% of pregnant women with a mechanical heart valve ... The Registry Of Pregnancy And Cardiac disease (ROPAC) is ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 “Harmonicas ... about a decade, primarily to help people with ... there are three developed systems,” says Dana Keller, ... substantively differ, the goals are much the same ... of some type of harmonica.” , The three ...
(Date:9/2/2014)... Fast hosting is a great choice for webmasters to ... hosting suppliers and announced that Arvixe, Bluehost and JustHost ... is hard to find a good fast hosting supplier. ... features, uptime, server speed and customer support. People can ... manager of Top10BestSEOHosting.com says. , Arvixe has a world-class ...
(Date:9/1/2014)... September 02, 2014 NAPW ... Healthcare, LLC as a 2014 Professional Woman of the ... for leadership in office management. As the largest, most-recognized ... virtually every industry and profession, the National Association of ... over 600,000 members and nearly 300 Local Chapters. , ...
Breaking Medicine News(10 mins):Health News:MichaelHusted.com Features Interview with Anthony Cantele of Cantele Kicking on His Role as a Kicking Coach and on Becoming a National Camp Series (NCS) Associate 2Health News:MichaelHusted.com Features Interview with Anthony Cantele of Cantele Kicking on His Role as a Kicking Coach and on Becoming a National Camp Series (NCS) Associate 3Health News:Mechanical heart valves increase pregnancy risk 2Health News:Mechanical heart valves increase pregnancy risk 3Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 3Health News:Top10BestSEOHosting.com Recommends Fast Web Hosting Suppliers 2Health News:National Association of Professional Women Announces Victoria Smith, Office Manager at Apex Healthcare, LLC, a 2014 Professional Woman of the Year 2
... ... ... ... ...
... ... relied on chest x-rays, stress tests, CAT scans and MRIs," said Dr. Myron Licht, ... in better understanding heart failure and cardiopulmonary disease because it provides objective information--primal physiology ... ...
... ... Cleveland medical malpractice attorney nets settlement for widow. , ... Cleveland, OH (PRWEB) February 23, 2010 -- Medical negligence ... reports that he and his firm have obtained a substantial monetary settlement on behalf of ...
... ... ... ... ...
... ... ... ... ...
... , ... ... ... ...
Cached Medicine News:Health News:BUAV Exposes Shocking Role Played by Laos in the International Trade in Primates for Research 2Health News:BUAV Exposes Shocking Role Played by Laos in the International Trade in Primates for Research 3Health News:BUAV Exposes Shocking Role Played by Laos in the International Trade in Primates for Research 4Health News:BUAV Exposes Shocking Role Played by Laos in the International Trade in Primates for Research 5Health News:Apex Heart Care, First Arizona Clinic to Install Shape-HF; New Medical Device Measures Patient Physiology to Define Shortness of Breath 2Health News:Apex Heart Care, First Arizona Clinic to Install Shape-HF; New Medical Device Measures Patient Physiology to Define Shortness of Breath 3Health News:Cleveland Medical Malpractice Attorney Obtains Settlement in Wrongful Death Case 2Health News:Cleveland Medical Malpractice Attorney Obtains Settlement in Wrongful Death Case 3Health News:Pew Report: Louisiana Failing to Address Children's Dental Health Crisis 2Health News:Pew Report: Louisiana Failing to Address Children's Dental Health Crisis 3Health News:Pew Report: Louisiana Failing to Address Children's Dental Health Crisis 4Health News:Pew Report: Louisiana Failing to Address Children's Dental Health Crisis 5Health News:Pew Report: Louisiana Failing to Address Children's Dental Health Crisis 6Health News:Pew Report: Louisiana Failing to Address Children's Dental Health Crisis 7Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 2Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 3Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 4Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 5Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 6Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 7Health News:Pew Report: Florida Failing To Address Children's Dental Health Crisis 2Health News:Pew Report: Florida Failing To Address Children's Dental Health Crisis 3Health News:Pew Report: Florida Failing To Address Children's Dental Health Crisis 4Health News:Pew Report: Florida Failing To Address Children's Dental Health Crisis 5Health News:Pew Report: Florida Failing To Address Children's Dental Health Crisis 6Health News:Pew Report: Florida Failing To Address Children's Dental Health Crisis 7
... Our thawing systems are automated, easy to ... from the outside environment by flexible snap-seal ... bacterial or viral contamination of the water. ... the systems can also accommodate bags of ...
Conventional Digitally-Controlled Water Baths...
... a flexible, self-expanding nitinol design intended to ... biliary system, is now available from Cook ... and Drug Administration. Incorporating the features that ... successful around the world, the Zilver 518 ...
... double spot test is a rapid, ... antibodies to T. cruzi in human ... samples. This test is intended primarily ... reactive samples should be confirmed by ...
Medicine Products: